| Age | 1) Minimum risk level from QRISK2 | 2) Risk threshold at which treatment becomes cost effective (from model) | Decision in clinical practice(a) |
|---|---|---|---|
| Male | |||
| 40 | 1.50% | 0.66% | Treat all |
| 50 | 4.00% | 1.84% | Treat all |
| 60 | 8.50% | 5.02% | Treat all |
| 70 | 16.40% | 9.72% | Treat all |
| 75 | 22% | 11.43% | Treat all |
| Female | |||
| 40 | 0.90% | 1.66% | Treat above 1.66% risk |
| 50 | 2.30% | 2.82% | Treat above 2.82% risk |
| 60 | 5.30% | 4.94% | Treat all |
| 70 | 11.70% | 7.53% | Treat all |
| 75 | 17.00% | 8.52% | Treat all |
Note: if the risk levels the model found were cost effective (column labelled 2) are lower than the minimum risk level (column labelled 1), then it is cost effective to treat everyone at that age, regardless of risk; otherwise, the model result is the lowest cost effective risk level.
From: Evidence review for initiating treatment
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.